Loading…

BCL2L12 protein overexpression is associated with favorable outcome in diffuse large B-cell lymphoma patients in the rituximab era

Saved in:

Bibliographic Details
Published in:	Leukemia & lymphoma 2016-09, Vol.57 (9), p.2199-2203
Main Authors:	Papageorgiou, Sotirios G., Kontos, Christos K., Foukas, Periklis G., Panopoulou, Eleni, Vasilatou, Diamantina, Rapti, Stamatia-Maria, Gkontopoulos, Konstantinos, Bazani, Efthimia, Panayiotides, Ioannis G., Dimitriadis, George, Scorilas, Andreas, Pappa, Vasiliki
Format:	Article
Language:	English
Subjects:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers, Pharmacological - metabolism Biomarkers, Tumor - genetics Biomarkers, Tumor - metabolism Gene Expression Regulation, Neoplastic HL-60 Cells Humans Lymphoma, Large B-Cell, Diffuse - diagnosis Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - genetics Lymphoma, Large B-Cell, Diffuse - mortality Muscle Proteins - genetics Muscle Proteins - metabolism Prognosis Proto-Oncogene Proteins c-bcl-2 - genetics Proto-Oncogene Proteins c-bcl-2 - metabolism Rituximab - administration & dosage Rituximab - therapeutic use Survival Analysis Treatment Outcome Up-Regulation - genetics
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!